GSK Files Japan's First Rotavirus Vaccine; Will Japan Become Next Battleground For Vaccine Makers?
This article was originally published in PharmAsia News
Executive Summary
GlaxoSmithKline announced Nov. 30 it is applying for approval for its rotavirus vaccine Rotarix with Japan's Ministry of Health, Labor and Welfare. If approved, it will become the first vaccine in Japan to prevent rotavirus gastroenteritis, a leading cause of diarrhea-related deaths in children
You may also be interested in...
GSK Names Former Sanofi Executive As President Of Japanese Affiliate
GlaxoSmithKline has appointed Philippe Fauchet, formerly a senior vice president at Sanofi-Aventis, as the new president of GSK's Japanese subsidiary
GSK Names Former Sanofi Executive As President Of Japanese Affiliate
GlaxoSmithKline has appointed Philippe Fauchet, formerly a senior vice president at Sanofi-Aventis, as the new president of GSK's Japanese subsidiary
MHLW To Establish Advisory Committee To Drive Vaccine Policy
To streamline vaccination decision making and better respond to future infectious disease outbreaks, Japan's Ministry of Health, Labor and Welfare will request ¥15 million in the fiscal year 2010 budget to establish a vaccination policy advisory body based on the U.S. Advisory Committee on Immunization Practices